摘要： 曲氟尿苷替匹嘧啶（TAS-102）是一种由曲氟尿苷（FTD）和胸苷磷酸化酶抑制剂（TPI）组成的口服化疗药物。体外和异种移植模型均证实TAS-102对5-氟尿嘧啶耐药的肿瘤具有抗肿瘤活性。基于Ⅲ期临床试验中TAS-102为患者带来生存获益，目前已被批准用于转移性结直肠癌和胃癌患者的三线治疗。近年来，有研究初步表明TAS-102在各种消化道肿瘤中均有一定疗效。本文总结了TAS-102在消化道肿瘤中的临床应用，并对TAS-102联合其他抗肿瘤药物的合理性及临床获益进行综述。

曲氟尿苷替匹嘧啶在消化道肿瘤中的研究进展

邹佳运, 张树玲, 王颖

中国医科大学附属盛京医院肿瘤科, 沈阳 110004

收稿日期:2022-07-16出版日期:2023-12-30发布日期:2023-12-12
通讯作者:王颖E-mail:wang_ying@sj-hospital.org
作者简介:邹佳运(1992-),男,主治医师,博士研究生
基金资助:国家自然科学基金（82103338）


关键词: 曲氟尿苷替匹嘧啶, 消化道肿瘤, 联合治疗, 结直肠癌
Abstract: Trifluridine-tipiracil (TAS-102) is an oral chemotherapeutic agent combination comprising a fluoropyrimidine (FTD) and a potent thymidine phosphorylase (TPI) inhibitor. TAS-102 is novel due to its antitumor activity against 5-fluorouracil resistant tumors, demonstrated both by in vitro models and xenografts. TAS-102 is currently approved as a third-line therapeutic strategy for metastatic colorectal and gastric cancer based on phaseⅢ randomized clinical trial data confirming survival benefits with TAS-102. Preliminary data from recent studies suggest a potential expanding role of TAS-102 in various gastrointestinal (GI) cancers. This article summarizes the clinical applications of TAS-102 in the treatment of GI cancers. Additionally, we discuss the rationale and clinical benefits of combining TAS-102 with other anticancer agents in patients with GI cancers.
Key words: trifluridine-tipiracil, gastrointestinal malignancies, combination therapy, colorectal cancer
PDF全文下载地址:

https://journal.cmu.edu.cn/CN/article/downloadArticleFile.do?attachType=PDF&id=3337